| Donna Olshefski Ott, DO | |
|
7 Upper Holland Road, Richboro, PA 18954 | |
| (215) 364-8040 | |
| (215) 364-3791 |
| Full Name | Donna Olshefski Ott |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 7 Upper Holland Road, Richboro, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730124777 | NPI | - | NPPES |
| 001900686 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS010896L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayada Home Health Care, Inc. | Jamison, PA | Home health agency |
| St Mary Medical Center | Langhorne, PA | Hospital |
| Doylestown Hospital | Doylestown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aria Health Physician Services | 3577467018 | 418 |
News Archive
Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.
The mechanism by which some bacteria are able to survive antibacterial treatment has been revealed for the first time by Hebrew University of Jerusalem researchers. Their work could pave the way for new ways to control such bacteria.
Atrial fibrillation, whose prevalence continues to rise, was described last year as the "new epidemic" in cardiovascular disease, even though AF can be successfully controlled by the detection and management of risk factors, by rhythm control treatments, and by the use of antithrombotic therapies.
Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.
› Verified 7 days ago
| Entity Name | Aria Health Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750949806 PECOS PAC ID: 3577467018 Enrollment ID: O20040224000045 |
News Archive
Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.
The mechanism by which some bacteria are able to survive antibacterial treatment has been revealed for the first time by Hebrew University of Jerusalem researchers. Their work could pave the way for new ways to control such bacteria.
Atrial fibrillation, whose prevalence continues to rise, was described last year as the "new epidemic" in cardiovascular disease, even though AF can be successfully controlled by the detection and management of risk factors, by rhythm control treatments, and by the use of antithrombotic therapies.
Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.
› Verified 7 days ago
| Entity Name | Drexel University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902900095 PECOS PAC ID: 5496664740 Enrollment ID: O20140729001682 |
News Archive
Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.
The mechanism by which some bacteria are able to survive antibacterial treatment has been revealed for the first time by Hebrew University of Jerusalem researchers. Their work could pave the way for new ways to control such bacteria.
Atrial fibrillation, whose prevalence continues to rise, was described last year as the "new epidemic" in cardiovascular disease, even though AF can be successfully controlled by the detection and management of risk factors, by rhythm control treatments, and by the use of antithrombotic therapies.
Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donna Olshefski Ott, DO Po Box 8500-6335, Philadelphia, PA 19178-6335 Ph: (215) 612-4000 | Donna Olshefski Ott, DO 7 Upper Holland Road, Richboro, PA 18954 Ph: (215) 364-8040 |
News Archive
Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.
The mechanism by which some bacteria are able to survive antibacterial treatment has been revealed for the first time by Hebrew University of Jerusalem researchers. Their work could pave the way for new ways to control such bacteria.
Atrial fibrillation, whose prevalence continues to rise, was described last year as the "new epidemic" in cardiovascular disease, even though AF can be successfully controlled by the detection and management of risk factors, by rhythm control treatments, and by the use of antithrombotic therapies.
Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.
› Verified 7 days ago
Dr. Jerry Margulies, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1057 Second Street Pike, Richboro, PA 18954 Phone: 215-710-2770 Fax: 215-710-2772 | |
Vijaya J Shah, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 862 Second Street Pike, Richboro, PA 18954 Phone: 215-322-9292 Fax: 215-322-4394 | |
Dr. Harvey N Lisgar, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Almshouse Rd, Suite 202, Richboro, PA 18954 Phone: 215-364-4141 Fax: 215-364-7162 | |
Gerry Aguinaldo Rosales Jr., M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 95 Almshouse Rd, Suite 103, Richboro, PA 18954 Phone: 215-357-5760 Fax: 215-357-5731 | |
Dr. Patti Anolik, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 910 2nd Street Pike, Richboro, PA 18954 Phone: 215-364-0777 Fax: 267-579-0720 | |
Ronald S Luber, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 778 Second Street Pike, Richboro, PA 18954 Phone: 215-942-2850 | |
Dr. Jennifer Minkovich, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 851 Bustleton Pike Unit 18, Richboro, PA 18954 Phone: 267-401-8518 |